Abstract
Leukocyte rolling, adhesion, transmigration and activation are features of vascular inflammation leading to atherosclerosis. In particular the interaction between platelets and leukocytes is a key process for adhesion of inflammatory cells to the vascular wall. The various mechanisms of the specific platelet-leukocyte interaction may provide a powerful target to prevent initiation and/or progression of atherosclerotic lesions.
Keywords: Atherosclerosis, EMMPRIN, monocytes, platelets, pharmacological inhibition, inflammation, P-Selectin, clopidogrel, cytokines, chemokines
Current Vascular Pharmacology
Title:Therapeutic Potential and Strategies Against Leukocyte-Platelet Interaction in Atherosclerosis
Volume: 10 Issue: 5
Author(s): Peter Seizer and Andreas E. May
Affiliation:
Keywords: Atherosclerosis, EMMPRIN, monocytes, platelets, pharmacological inhibition, inflammation, P-Selectin, clopidogrel, cytokines, chemokines
Abstract: Leukocyte rolling, adhesion, transmigration and activation are features of vascular inflammation leading to atherosclerosis. In particular the interaction between platelets and leukocytes is a key process for adhesion of inflammatory cells to the vascular wall. The various mechanisms of the specific platelet-leukocyte interaction may provide a powerful target to prevent initiation and/or progression of atherosclerotic lesions.
Export Options
About this article
Cite this article as:
Seizer Peter and E. May Andreas, Therapeutic Potential and Strategies Against Leukocyte-Platelet Interaction in Atherosclerosis, Current Vascular Pharmacology 2012; 10 (5) . https://dx.doi.org/10.2174/157016112801784585
DOI https://dx.doi.org/10.2174/157016112801784585 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diet Bioactive Compounds: Implications for Oxidative Stress and Inflammation in the Vascular System
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Current Pharmaceutical Design Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy Phase-Change Contrast Agents for Imaging and Therapy
Current Pharmaceutical Design Heme Oxygenase-Derived Carbon Monoxide Restores Vascular Function in Type 1 Diabetes
Drug Metabolism Letters Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Protective Effects of TRPV1 Activation Against Cardiac Ischemia/ Reperfusion Injury is Blunted by Diet-Induced Obesity
Cardiovascular & Hematological Disorders-Drug Targets Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Erythropoietin Treatment in Patients with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Drug Delivery Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology